Adrenal Nodule
Learn about adrenal nodule diagnosis, including clinical documentation and medical coding for adrenal masses, adrenal tumors, and adrenal lesions. Find information on healthcare best practices for identifying and managing an adrenal mass, adrenal tumor, or adrenal lesion. This resource offers guidance on adrenal nodule diagnosis, supporting accurate medical coding and comprehensive clinical documentation.
Growth in the adrenal gland, can be benign or cancerous.
Often asymptomatic. May cause high blood pressure, hormonal imbalances, or abdominal pain.
Detected incidentally on imaging (CT, MRI) or during evaluation for hormonal issues.
ICD-10 Code Families
Complete code families applicable to D35.00
When to use each related code
| Description | When to use |
|---|---|
| Growth in the adrenal gland. Can be benign or cancerous. | Use for any abnormal growth found in the adrenal gland during imaging or examination. Consider size, imaging characteristics, and hormonal activity. |
| Benign adrenal tumor producing excess hormones. | Use when hormone overproduction is confirmed (e.g., pheochromocytoma, Conn's syndrome). Specify the hormone if known. |
| Non-functioning adrenal adenoma. Usually benign and asymptomatic. | Use for incidentally discovered, non-hormone-producing adrenal nodules. Usually small and require monitoring. |
Best-practice checklist
- ✓Document nodule size, location, and characteristics (e.g., homogenous, heterogeneous).
- ✓Describe imaging findings: US, CT, or MRI adrenal nodule.
- ✓Specify if incidental finding or if causing symptoms.
- ✓Include hormonal evaluation results (if performed).
- ✓Code using ICD-10 D35.0 Adrenal gland adenoma.
Common pitfalls to avoid
Missing documentation specifying right, left, or bilateral adrenal nodule impacts coding accuracy and reimbursement.
Incomplete documentation distinguishing benign from malignant adrenal masses affects coding, treatment, and surveillance planning.
Lack of clarity on whether the adrenal nodule is incidental or causing symptoms can lead to coding and clinical management discrepancies.
Best-practice tips
- 01Document size, shape, and imaging characteristics for accurate adrenal nodule coding.
- 02Use precise adrenal lesion terminology (mass vs. tumor) for compliant clinical documentation.
- 03Correlate imaging findings with hormonal evaluation for adrenal mass diagnosis and CDI.
- 04For incidentaloma, specify if hormonally active for proper adrenal tumor ICD-10 coding.
- 05Regular surveillance imaging crucial for indeterminate adrenal nodules, document follow-up plan.
Step-by-step checklist
- 1
Confirm nodule size and imaging characteristics (ICD-10 E27.8, SNOMED CT 307257003).
- 2
Assess hormonal function; evaluate for excess cortisol, aldosterone, catecholamines.
- 3
Review patient history for cancer, hypertension, or other relevant conditions.
- 4
Consider further imaging (CT, MRI) if indicated for size or characteristics.
Ready-to-paste narrative
Patient presents with concerns regarding a possible adrenal nodule, also referred to as an adrenal mass, adrenal tumor, or adrenal lesion. Review of systems includes detailed inquiry regarding symptoms such as abdominal pain, flank pain, back pain, unexplained weight changes, changes in blood pressure (including hypertension or hypotension), fatigue, and hormonal imbalances. Physical examination findings are documented, including palpation of the abdomen and assessment for any signs of Cushing syndrome, Conn syndrome, or pheochromocytoma. Differential diagnosis includes benign adrenal adenoma, adrenocortical carcinoma, pheochromocytoma, myelolipoma, and metastatic disease. Diagnostic workup may include abdominal ultrasound, CT scan of the adrenal glands with and without contrast, MRI of the adrenal glands, hormonal blood tests (cortisol, aldosterone, renin, catecholamines), and 24-hour urine collection for metanephrines and catecholamines. Management plan is based on imaging characteristics, hormonal evaluation, and patient symptoms. Options include watchful waiting with serial imaging, further biochemical testing, fine-needle aspiration biopsy, or surgical resection (adrenalectomy) for suspicious or symptomatic lesions. Patient education provided regarding the nature of adrenal nodules, potential complications, and the importance of follow-up care. ICD-10 codes (e.g., D35.0, D35.1 depending on laterality and specific diagnosis), CPT codes for procedures (e.g., imaging, biopsy, adrenalectomy) will be assigned based on the final diagnosis and treatment plan. The patient's risk factors, family history, and relevant medical history are documented and considered in the assessment. Referral to endocrinology or surgical oncology may be warranted depending on the final diagnosis and management plan.
Common questions and answers
How can I differentiate between benign and malignant adrenal nodules based on imaging characteristics like size, shape, and CT attenuation values?+
Differentiating benign from malignant adrenal nodules requires a comprehensive evaluation of imaging characteristics. Size is a crucial factor, with nodules larger than 4 cm warranting closer scrutiny for malignancy. Shape and CT attenuation values also provide important clues. Irregular shapes, heterogeneous enhancement, and high attenuation values (especially >10 Hounsfield Units on non-contrast CT) raise suspicion for malignancy. However, these features are not definitive. Washout rate on contrast-enhanced CT can further aid differentiation, with rapid washout suggesting a benign adenoma. Ultimately, a combination of imaging findings, patient risk factors, and hormonal evaluation is often necessary for accurate characterization. Explore how S10.AI can streamline the analysis of adrenal nodule imaging characteristics for improved diagnostic accuracy.
What is the recommended follow-up imaging protocol for incidentally discovered, non-functioning adrenal nodules based on size and risk factors?+
The recommended follow-up imaging protocol for incidentally discovered, non-functioning adrenal nodules varies based on size and patient-specific risk factors for malignancy. Small, homogenous nodules (<4 cm) with benign imaging characteristics in low-risk patients may not require follow-up imaging. However, nodules between 4-6 cm should typically undergo repeat imaging within 6-12 months. For nodules >6 cm or those with suspicious features, further evaluation with dedicated adrenal protocol CT or MRI is warranted. Patients with a history of malignancy or endocrine disorders require individualized follow-up strategies. Consider implementing S10.AI's decision support tools for personalized adrenal nodule management based on current guidelines.
When is adrenal biopsy indicated for an adrenal nodule, and what are the potential risks and benefits of this procedure?+
Adrenal biopsy is typically reserved for specific situations, primarily when there is a high suspicion of malignancy despite inconclusive imaging and hormonal workup. It is also considered when a patient has a history of extra-adrenal malignancy and an indeterminate adrenal nodule is detected. Benefits include obtaining a tissue diagnosis, which can guide treatment decisions. However, the procedure carries risks, including bleeding, infection, and potential needle track seeding of malignant cells. The risk of non-diagnostic results also exists. Therefore, the decision to perform an adrenal biopsy must be carefully weighed against the potential risks and benefits in each individual case. Learn more about S10.AI's resources for optimizing adrenal nodule assessment and reducing the need for invasive procedures.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.